|
|
|
Guardant Health Inc (NASDAQ: GH) |
|
|
|
| |
Guardant Health Inc Outlook |
On February 21 2025 the Guardant Health Inc provided following guidance
nnGuardant Health Inc. Offers Financial Insights and Projections for 2025nn
PALO ALTO, Calif. – Guardant Health, Inc. (Nasdaq: GH), a prominent player in the realm of precision oncology, has disclosed its financial outcomes for both the fourth quarter and the full year, which concluded on December 31, 2024.
### Fourth Quarter 2024 Financial Highlights:
For the three-month period ending December 31, 2024, the company demonstrated notable growth compared to the corresponding period in 2023. Here are the key figures:
- nnTotal Revenuenn: The company recorded an impressive total revenue of $201.8 million, reflecting a substantial increase of 30% year-over-year.
- nnOncology Clinical Testsnn: Guardant Health reported approximately 57,300 oncology clinical tests performed, exclusive of the Shield test.
- nnBiopharma Testsnn: In addition, the company conducted around 11,050 tests for biopharmaceutical clients.
### 2025 Financial Outlook:
While Guardant Health has laid out its financial results, specific details regarding the projections for 2025 have not been disclosed in this summary. The company has provided a general outlook, indicating confidence in continued growth and operational success. For deeper insights and to explore the comprehensive financial guidance for 2025, stakeholders are encouraged to refer to the complete report.
This announcement underscores Guardant Health's commitment to advancing precision oncology and its strategic focus on expanding its testing capabilities to better serve both clinical and biopharma markets. Keep an eye on further communications from the company for more detailed projections and developments as we progress through 2025.
### Conclusion:
Overall, Guardant Health's results for 2024 signal a positive trajectory for the company, bolstered by significant revenue growth and continued investment in its testing technologies. The market awaits more specific guidance for 2025, which is anticipated to shed light on the company's plans for further innovation and expansion.,
|
On May 10 2024 the Guardant Health Inc provided following guidance
y, compared to the first quarter of 2023. Gross profit of $114.6 million for the first quarter of 2024, representing a gross margin of 68% Cash and cash equivalents of $502.7 million as of March 31, 2024 Total operating expenses of $150.7 million for the first quarter of 2024, an increase of 25% compared to the first quarter of 2023 Net loss of $36.0 million for the first quarter of 2024, compared to a net loss of $29.9 million in the first quarter of 2023.
Guardant Health also announced an increase in its 2024 revenue guidance, now expecting revenue to be in the range of $720 million to $740 million, up from the previous guidance of $700 million to $720 million. This increase is driven by strong demand for the company's precision oncology testing services and continued growth in both clinical and biopharmaceutical customer bases.
CEO of Guardant Health, Helmy Eltoukhy, commented on the financial results, stating, We are pleased with our strong start to 2024, with double-digit revenue growth and continued expansion of our customer base. We remain focused on driving adoption of our innovative testing solutions and accelerating our path to profitability.
Overall, Guardant Health's first quarter financial results and increased revenue guidance for 2024 demonstrate the company's continued growth and success in the precision oncology market. Investors and stakeholders can expect to see further advancements and achievements from Guardant Health in the coming months.
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
